Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | LDLR | P01130 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14182614 | 0.88 | HDAC1 (0.43) | HDAC1DHODHTRPV1SMN1; SMN2 | |
| SCHEMBL8263365 | 0.86 | HDAC1 (0.42) | HDAC1DHODHTRPV1SMN1; SMN2 | |
| SCHEMBL4897229 | 0.79 | HDAC1 (0.52) | HDAC1DHODHNPC1RAB9ATRPV1 | |
| SCHEMBL4897402 | 0.79 | HDAC1 (0.59) | HDAC1NPC1RAB9ATRPV1POLB | |
| SCHEMBL4894599 | 0.79 | HDAC1 (0.56) | HDAC1NPC1RAB9ATRPV1POLB | |
| SCHEMBL5821765 | 0.78 | HDAC1 (0.58) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL4897276 | 0.76 | HDAC1 (0.68) | HDAC1 | |
| SCHEMBL4893482 | 0.76 | KMT2A (0.58) | HDAC1NPC1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL4893491 | 0.76 | KMT2A (0.58) | HDAC1NPC1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL18573121 | 0.74 | DHODH (0.55) | DHODHNPC1RAB9ATRPV1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885DHODH 3390/4885NPC1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.